Literature DB >> 17009941

Antibiotic resistance in Neisseria gonorrhoeae is diminishing available treatment options for gonorrhea: some possible remedies.

John Tapsall1.   

Abstract

Gonorrhea is essentially out of control in many settings and high disease rates are coupled with the spread of multiresistant gonococci. Increases in quinolone resistance have followed loss of the penicillins and tetracyclines as useful treatments. Decreasing susceptibility to third-generation cephalosporins is also reported. Over-reliance on antibiotic treatment as a disease control measure in settings with high disease rates and poor control of antibiotic usage is a significant contributor to the antimicrobial resistance reported. Conversely, containment of resistance is more likely to be achieved when combined with disease control principles shown to be effective. However, until a higher priority is given to funding for sexually transmitted diseases, this prospect is unlikely to eventuate and the possibility of untreatable gonorrhea becomes more real.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17009941     DOI: 10.1586/14787210.4.4.619

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  20 in total

1.  Molecular analyses of TEM genes and their corresponding penicillinase-producing Neisseria gonorrhoeae isolates in Bangkok, Thailand.

Authors:  Shu-Ichi Nakayama; Chanwit Tribuddharat; Sasiprapa Prombhul; Ken Shimuta; Somporn Srifuengfung; Magnus Unemo; Makoto Ohnishi
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

2.  Using crude whole-genome assemblies of Neisseria gonorrhoeae as a platform for strain analysis: clonal spread of gonorrhea infection in Saskatchewan, Canada.

Authors:  Sinisa Vidovic; Carolyn Caron; Ali Taheri; Sidharath D Thakur; Timothy D Read; Anthony Kusalik; Jo-Anne R Dillon
Journal:  J Clin Microbiol       Date:  2014-07-23       Impact factor: 5.948

3.  In Vitro selection of Neisseria gonorrhoeae mutants with elevated MIC values and increased resistance to cephalosporins.

Authors:  Steven R Johnson; Yonatan Grad; Satishkumar Ranganathan Ganakammal; Mark Burroughs; Mike Frace; Marc Lipsitch; Ryan Weil; David Trees
Journal:  Antimicrob Agents Chemother       Date:  2014-09-08       Impact factor: 5.191

4.  Does the Cervicovaginal Microbiome Facilitate Transmission of Neisseria gonorrhoeae From Women to Men? Implications for Understanding Transmission of Gonorrhea and Advancing Vaccine Development.

Authors:  William M Shafer
Journal:  J Infect Dis       Date:  2016-07-28       Impact factor: 5.226

Review 5.  Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea.

Authors:  Magnus Unemo; Robert A Nicholas
Journal:  Future Microbiol       Date:  2012-12       Impact factor: 3.165

6.  Gonococcal resistance: are cephalosporins next?

Authors:  Robert D Kirkcaldy; Ronald C Ballard; Deborah Dowell
Journal:  Curr Infect Dis Rep       Date:  2011-04       Impact factor: 3.725

Review 7.  The use of cephalosporins for gonorrhea: the impending problem of resistance.

Authors:  Pennan M Barry; Jeffrey D Klausner
Journal:  Expert Opin Pharmacother       Date:  2009-03       Impact factor: 3.889

8.  ksgA mutations confer resistance to kasugamycin in Neisseria gonorrhoeae.

Authors:  Paul M Duffin; H Steven Seifert
Journal:  Int J Antimicrob Agents       Date:  2008-12-18       Impact factor: 5.283

9.  Various penA mutations together with mtrR, porB and ponA mutations in Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime or ceftriaxone.

Authors:  Sang-Guk Lee; Hyukmin Lee; Seok Hoon Jeong; Dongeun Yong; Gyung Tae Chung; Yeong Seon Lee; Yunsop Chong; Kyungwon Lee
Journal:  J Antimicrob Chemother       Date:  2010-01-21       Impact factor: 5.790

10.  Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone.

Authors:  David M Whiley; E Athena Limnios; Sanghamitra Ray; Theo P Sloots; John W Tapsall
Journal:  Antimicrob Agents Chemother       Date:  2007-06-25       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.